Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.
Several other brokerages have also recently commented on ACRV. Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Jefferies Financial Group restated a “buy” rating on shares of Acrivon Therapeutics in a research report on Wednesday, November 11th. Finally, Citizens Jmp reaffirmed a “market outperform” rating on shares of Acrivon Therapeutics in a report on Tuesday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.
Get Our Latest Stock Analysis on ACRV
Acrivon Therapeutics Stock Performance
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. Sell-side analysts predict that Acrivon Therapeutics will post -1.69 EPS for the current year.
Insider Activity
In other news, CEO Peter Blume-Jensen sold 14,036 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the completion of the transaction, the chief executive officer directly owned 2,230,052 shares of the company’s stock, valued at $4,928,414.92. This trade represents a 0.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,444 shares of company stock valued at $36,320 over the last quarter. 10.50% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Acrivon Therapeutics
Large investors have recently bought and sold shares of the stock. StoneX Group Inc. acquired a new position in shares of Acrivon Therapeutics in the third quarter worth $43,000. Spark Investment Management LLC acquired a new stake in shares of Acrivon Therapeutics during the second quarter valued at $50,000. Empowered Funds LLC acquired a new stake in shares of Acrivon Therapeutics during the third quarter valued at $117,000. Renaissance Technologies LLC increased its position in Acrivon Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock worth $1,054,000 after purchasing an additional 124,271 shares in the last quarter. Finally, Marshall Wace LLP increased its position in Acrivon Therapeutics by 2.0% during the 3rd quarter. Marshall Wace LLP now owns 542,344 shares of the company’s stock worth $1,112,000 after purchasing an additional 10,488 shares in the last quarter. Institutional investors and hedge funds own 71.62% of the company’s stock.
About Acrivon Therapeutics
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.
See Also
- Five stocks we like better than Acrivon Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
